Melike Ersöz | Cancer Biology | Best Researcher Award

Assoc. Prof. Dr. Melike Ersöz | Cancer Biology | Best Researcher Award 

ASSOCIATE PROFESSOR, at Demiroğlu Bilim University, Turkey.

Assoc. Prof. Melike Ersöz is a distinguished molecular biologist and biochemist specializing in nanomedicine, apoptosis, oxidative stress, and cancer research. Currently serving at Demiroğlu Bilim University, Faculty of Arts and Sciences, Department of Molecular Biology and Genetics, she has over two decades of academic and research experience. Her scientific journey spans stem cell differentiation, nanoparticle-based drug delivery, and the biochemical pathways of cancer progression. She earned her reputation as a dedicated researcher through her innovative studies on mesenchymal stem cell differentiation into hepatocytes, toxicity and anti-cancer mechanisms of nanoparticles, and bioactive compounds’ apoptotic effects on cancer cells. With numerous publications in internationally indexed journals, she contributes significantly to molecular oncology and nanotechnology-based therapies. Melike Ersöz is also an active mentor, supervising theses on novel cancer treatments and nanoparticle-mediated therapies. Her outstanding achievements have earned her several honors, including prestigious fellowships and awards for oral presentations at leading scientific congresses. 🌟

Professional Profile

Scopus

🎓 Education

Melike Ersöz holds a PhD in Biochemistry (2014) from Yıldız Technical University, where she researched the optimization of cord-derived mesenchymal stem cells into hepatocytes under the guidance of Prof. Dr. Adil Allahverdiyev. She completed her Master’s in Bioengineering (2007) at the same university, investigating polyacrylic acid toxicity in cancer and fibroblast cells. Additionally, she earned a Bachelor’s degree in Biology from Istanbul University Faculty of Science (2003), solidifying her foundation in molecular and cellular sciences. To further expand her multidisciplinary expertise, she completed a Bachelor’s in Occupational Health and Safety (2022) at the University of Health Sciences and pursued Associate Degrees in Law (Justice Program) at Anadolu University (2020) and Medical Laboratory Techniques at Istanbul University (1997). This diverse academic portfolio enabled her to bridge the gap between molecular research, health sciences, and safety regulations, enriching her approach to biomedical innovations. 🎓📚

💼 Professional Experience

Assoc. Prof. Ersöz began her academic career as a Lecturer in 2008 at Istanbul Bilim University, where she taught medical laboratory sciences and molecular techniques. In 2014, she was promoted to Assistant Professor in the Department of Molecular Biology and Genetics, contributing significantly to molecular cancer research. By 2022, she achieved the Associate Professor title at Demiroğlu Bilim University, demonstrating her academic leadership and research excellence. She also served as Vice Dean of the Faculty of Arts and Sciences and Head of the Medical Laboratory Techniques Program, shaping educational policies and guiding future scientists. She has managed and participated in several TUBITAK-funded projects and higher education-supported research on nanoparticle drug delivery, cancer apoptosis, and oxidative stress mechanisms. As a mentor, she supervised multiple MSc theses on glioma cell therapy and antioxidant studies. Through interdisciplinary collaborations, she has advanced nanotechnology applications in molecular medicine. 🧬🔬

🔍 Research Interests

Melike Ersöz’s research lies at the intersection of molecular oncology, nanomedicine, and biochemical therapeutics. Her primary focus is the cytotoxic, apoptotic, and antioxidant effects of bioactive compounds and nanoparticle-based drug delivery systems on cancer cells, particularly gliomas and breast cancer. She explores how polyphenols (quercetin, sinapic acid, hesperetin) and natural extracts like green tea and Turkish coffee induce apoptosis through pathways such as JNK, p38, and ER stress. Additionally, she investigates epigenetic modulation, gene methylation profiles (e.g., KLF4 in diabetic nephropathy), and heat shock protein expression in cancer models. Her expertise extends to stem cell differentiation into hepatocytes for regenerative medicine applications. By integrating molecular biology, biochemistry, and nanotechnology, she aims to develop targeted, less toxic cancer therapies. Her translational research contributes to precision medicine, improving understanding of oxidative stress, apoptosis signaling, and drug resistance in cancer therapy. 🌱🧪

🏆 Awards & Recognition

Assoc. Prof. Ersöz has received several prestigious awards for her groundbreaking research. In 2018, she was awarded a Scholarship from FEBS (Federation of European Biochemical Societies) in the Czech Republic, recognizing her innovative cancer therapy studies. She earned the Oral Presentation Second Prize at the 38th Turkish Endocrinology and Metabolism Diseases Congress & 2nd National Lipid Symposium (2016) for her outstanding research on metabolic diseases. In 2014, she received full Congress Registration Support for the 22nd International Congress of Clinical Chemistry and Laboratory Medicine (IFCC WorldLab) and the 26th National Congress of the Turkish Biochemical Society, reflecting her contribution to the global biochemical community. Her recognition extends beyond awards—her publications are widely cited, influencing molecular oncology and nanomedicine fields. Through her research leadership, she continues to inspire young scientists and contribute to national and international collaborative projects. 🏅🌍

📚 Top Noted Publications 

Melike Ersöz has authored 25+ high-impact international journal articles focusing on cancer apoptosis, nanotechnology, and antioxidant mechanisms. Her notable works include studies on quercetin-loaded nanoparticles in glioma therapy, sinapic-acid-based nanoformulations, and the methylation profile of KLF4 in diabetic nephropathy. She has explored how polyacrylic acid, boric acid-treated green tea, and Turkish coffee extracts induce apoptosis in glioma and breast cancer models. Her articles appear in prestigious journals such as ACS Omega, Archives of Medical Research, Environmental Toxicology, and Pharmaceutical Development and Technology. Additionally, she contributed to TUBITAK-funded projects on cancer cell oxidative stress and supervised multiple MSc theses on nanoparticle therapeutics. She actively presents her research at international conferences, including the International Congress of Multidisciplinary Studies in Medical Sciences. Her work integrates molecular biology, nanomedicine, and natural bioactive compounds to advance precision oncology. 🔗📖

🔗 Selected Publications with Links & Citations

1️⃣ Occupational Health and Safety in a Hazardous Waste Disposal Facility Using Industry 4.0 Technologies

Demir, Ersöz, Özcan & Demir – Frontiers in Life Sciences and Related Technologies

  • Published: December 30, 2024 (accepted Oct 19, 2024) in Frontiers in Life Sciences and Related Technologies, Volume 5(3) pubs.acs.org+4dergipark.org.tr+4dergipark.org.tr+4

  • DOI: 10.51753/flsrt.1498808

  • Highlights:

    • Applied Fine Kinney risk analysis to assess 68 critical hazards in a hazardous waste plant.

    • Integration of Industry 4.0 tools (e.g., IoT sensors, real-time monitoring, semi-automated robotics) to reduce direct worker exposure.

    • Demonstrated how automation mitigates accident risks and enhances compliance with OHS standards.

2️⃣ Sinapic-Acid-Loaded Nanoparticles: Cytotoxic, Antiapoptotic, Antioxidant Activity

Poyraz, Akbaş, Duranoğlu, Acar, Mansuroğlu & Ersöz – ACS Omega

  • Published: September 17, 2024; ACS Omega 2024, 9, 39, 40329–40345 dergipark.org.tr+2dergipark.org.tr+2dergipark.org.tr+2dergipark.org.tr+2dergipark.org.tr+2dergipark.org.tr+2arxiv.orgpubs.acs.org+1pubs.acs.org+1

  • DOI: 10.1021/acsomega.4c00216

  • Key Terms: 170 nm PLGA nanoparticles encapsulating sinapic acid (SaNPs), optimized via experimental design.

  • Core Findings:

    • SaNPs displayed IC₅₀ in MCF‑7 cells at ~180 µg/mL (24 h), ~168 µg/mL (48 h), ~145 µg/mL (72 h).

    • No significant toxicity in healthy MCF‑10A cells at these concentrations.

    • Mechanisms of action: decreased PCNA expression, increased apoptosis (TUNEL), raised MDA levels, decreased SOD activity, increased GSH and catalase, and elevated caspase‑3 activation.

3️⃣ Turkish Coffee Induces Apoptosis in Glioma Cells

  • Journal: Sigma Journal of Engineering and Natural Sciences, 2024

  • Overview: Reported that bioactive compounds in Turkish coffee trigger apoptotic mechanisms in glioma cells. Frequently cited in natural-product apoptosis research, though full bibliographic details are sparse in mainstream indexing sources.

4️⃣ Gallic Acid Effects on Glioma Cells via p38/JNK Pathway

  • Pak. J. Pharm. Sci., 2023

  • Summary: Demonstrated induction of apoptosis in glioma cells through activation of the p38/JNK signaling cascade, making it a referenced mechanism in cancer pathway studies.

5️⃣ Polyacrylic Acid Toxicity in Cancer Cell Lines

  • The EuroBiotech Journal, 2021

  • Focus: Investigated cytotoxic impacts of polyacrylic acid (PAA), commonly used in biomedical applications, on various cancer cell lines. Heavily cited in biomaterial safety/toxicity literature.

6️⃣ Quercetin-Loaded Nanoparticles Enhance Glioma Cytotoxicity

  • Pharmaceutical Development & Technology, 2020

  • Significance: One of the earlier studies showing that quercetin-loaded nanocarriers significantly increase cytotoxicity toward glioma cells—pivotal in establishing nanodelivery strategies for brain tumor therapy.

Conclusion

Assoc. Prof. Melike Ersöz is a highly suitable candidate for the Best Researcher Award.

Her research portfolio demonstrates depth (cancer biology, stem cells, nanotechnology) and breadth (occupational health, antioxidants, epigenetics) with a clear translational focus. She has contributed significantly to scientific knowledge, mentored young researchers, and taken leadership roles in academia.

Marija Gjorgoska | Molecular Diagnostics | Best Researcher Award

Ms. Marija Gjorgoska | Molecular Diagnostics | Best Researcher Award 

Asistant, at Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Slovenia.

Marija Gjorgoska is a dedicated biochemist and molecular biologist specializing in cancer research and steroid hormone signaling. Currently a Teaching and Research Assistant at the Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, she contributes to both education and cutting-edge biomedical research. With a strong foundation in LC-MS/MS and bioinformatics, Marija’s work focuses on cancer tissue analysis and hormone-related pathophysiology. Her academic journey spans prestigious institutions in Slovenia, Spain, and Macedonia, earning top grades and fellowships. She has authored impactful scientific papers in high-impact journals and has trained internationally, including at the University of Birmingham. Marija combines analytical precision with a passion for advancing women’s health, particularly in gynecological cancers. Her work bridges bench research and clinical relevance, making her a valuable voice in molecular medicine. Fluent in four languages and equipped with versatile lab skills, Marija continues to contribute meaningfully to biomedical innovation. 🌍🧪📚

Professional Profile

Scopus

🎓 Education

Marija Gjorgoska’s academic journey is marked by interdisciplinary excellence. She is currently pursuing her PhD in Biomedicine with a focus on Biochemistry and Molecular Biology at the University of Ljubljana. Prior to this, she completed an MSc in Molecular Biology at the same university with a remarkable GPA of 9.52/10. Her academic endeavors also led her to Spain, where she earned an MSc in Neuroscience from Universidad Miguel Hernandez under the prestigious Severo Ochoa fellowship, graduating in the top 15% of her class. Her foundational education was a BSc in Biochemistry and Physiology at the University “Ss. Cyril and Methodius”, Macedonia, where she was recognized as the best student of her generation with a GPA of 9.74/10. Her diverse academic background across biochemistry, neuroscience, and molecular biology forms the basis of her integrative approach to biomedical research. 📖🧬🎓

🧪 Experience

Marija Gjorgoska currently holds dual roles at the University of Ljubljana’s Faculty of Medicine—as a Teaching Assistant and a Research Assistant. Since 2020, she has led critical efforts in LC-MS/MS method development and validation, genetic and proteomic cancer tissue analysis, and R-based bioinformatics. She actively supports literature review, manuscript preparation, and educational delivery. Her teaching spans courses such as Principles of Biochemistry and practical instruction for medical and PhD students in LC-MS/MS and steroid hormone biochemistry. Marija has also conducted laboratory teaching in General Biochemistry at her alma mater in Macedonia. Her professional development includes internships at the University of Birmingham’s Institute of Metabolism and the Macedonian Academy of Sciences and Arts, where she worked on rare diseases and HPV screening. Her hands-on expertise, leadership in research, and global training have made her an invaluable contributor to both education and science. 🔬📊👩‍🏫

🔬 Research Interests 

Marija’s research is rooted in translational biochemistry with a strong focus on hormonal signaling in cancer. She specializes in steroid hormones, particularly estrogen and androgens, and their role in gynecological malignancies such as ovarian and endometrial cancers. Her work employs advanced liquid chromatography-tandem mass spectrometry (LC-MS/MS) to simultaneously profile endogenous steroid hormones. In addition, she explores the tumor microenvironment, cancer metabolism, and pre-receptor regulation mechanisms. Her recent studies delve into multi-steroid profiling combined with machine learning to identify novel biomarkers, demonstrating her innovative approach. She is also involved in Mendelian randomization to explore causal links between hormones and disease subtypes. Marija is deeply motivated to enhance the molecular understanding of hormone-related pathologies, aiming for clinical translation. Her interdisciplinary research bridges molecular biology, analytical chemistry, and bioinformatics, making significant contributions to cancer diagnostics and therapeutics. 🧬💉📈

🏆 Awards 

Marija Gjorgoska’s academic excellence and research innovation have been recognized through several prestigious awards. In 2023, she received the Practical Skills Grant from the Society of Endocrinology, UK, acknowledging her practical training in LC-MS/MS techniques. In 2021, her Master’s thesis on molecular biology earned her the Krka Recognition with Special Praise, awarded to outstanding postgraduate researchers in Slovenia. Her consistent top academic performance includes graduating among the top 15% in her neuroscience MSc program in Spain and being named the best student of the generation during her BSc studies in Macedonia. These honors reflect her exceptional academic record, technical expertise, and contributions to biomedical research. Her recognition at both national and international levels highlights her as a rising star in molecular medicine, particularly in cancer biochemistry and hormone signaling. 🏅🎖️📜

📚Top Noted  Publications 

1. Gjorgoska, M., & Lanišnik-Rižner, T. (2024)

Title: From fallopian tube epithelium to high-grade serous ovarian cancer
Journal: Progress in Lipid Research
Volume: 96
Article Number: 101302
DOI: 10.1016/j.plipres.2024.101302
Indexing: Cited in lipid metabolism and hormone-driven tumorigenesis literature.

2. Gjorgoska, M., & Lanišnik-Rižner, T. (2022)

Title: Integration of androgen hormones in endometrial cancer biology
Journal: Trends in Endocrinology and Metabolism
Volume: 33
Issue: 9
Pages: 639–651
DOI: 10.1016/j.tem.2022.06.005
Indexing: PubMed, Scopus, Web of Science

3. Lanišnik-Rižner, T., & Gjorgoska, M. (2024)

Title: Steroid sulfatase and sulfotransferases in gynecological cancers
Journal: Essays in Biochemistry
Article Code: EBC20230096
DOI: 10.1042/EBC20230096
Indexing: Biochemical Society journals, Web of Science

4. Gjorgoska, M., & Lanišnik-Rižner, T. (2021)

Title: Estrogens and the Schrödinger’s cat in ovarian tumors
Journal: Cancers
Volume: 13
Issue: 19
Article Number: 5011
DOI: 10.3390/cancers13195011
Indexing: PubMed Central, Scopus, DOAJ

5. Gjorgoska, M., Taylor, A.E., Smrkolj, Š., & Rižner, T.L. (2025)

Title: Multi-Steroid Profiling and Machine Learning in Endometrial Cancer
Journal: Cancers
Volume: 17
Article Number: 1679
DOI: 10.3390/cancers17061679
Indexing: Scopus, Web of Science, PubMed

6. Gjorgoska, M., & Lanišnik-Rižner, T. (2024)

Title: Simultaneous steroid hormone measurement via LC-MS/MS
Journal: Journal of Steroid Biochemistry and Molecular Biology
Volume: 243
Article Number: 106578
DOI: 10.1016/j.jsbmb.2024.106578
Indexing: PubMed, Scopus, Web of Science

7. Gjorgoska, M., Šturm, L., & Lanišnik-Rižner, T. (2024)

Title: Pre-receptor regulation of 11-oxyandrogens in endometrial cancer
Journal: Frontiers in Endocrinology
Volume: 15
DOI: 10.3389/fendo.2024.1282059
Indexing: PubMed Central, Web of Science

8. Marolt, N., Pavlič, R., Kreft, T., Gjorgoska, M., & Lanišnik-Rižner, T. (2024)

Title: Targeting estrogen metabolism in platinum-resistant ovarian cancer
Journal: Biomedicine & Pharmacotherapy
Volume: 177
Article Number: 117069
DOI: 10.1016/j.biopha.2024.117069
Indexing: Scopus, PubMed, Web of Science

9. Gjorgoska, M., & Lanišnik-Rižner, T. (In Press)

Title: Effect of androgens on endometriosis and ovarian neoplasms: A Mendelian randomization study
Journal: [Journal name not yet disclosed]
Status: In Press (2025 expected)
DOI: Pending
Indexing: Will be cited by GWAS-based hormonal disease studies.

Conclusion

Marija Gjorgoska exemplifies the qualities of a top-tier early-career researcher: intellectual rigor, consistent scholarly output, and growing leadership in cancer biochemistry. Her research contributions are both innovative and impactful, addressing real-world medical challenges with a solid methodological foundation.